Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial by unknown
STUDY PROTOCOL Open Access
Preoperative chemoradiation with
paclitaxel-carboplatin or with fluorouracil-
oxaliplatin—folinic acid (FOLFOX) for
resectable esophageal and junctional
cancer: the PROTECT-1402, randomized
phase 2 trial
Mathieu Messager1,2,3, Xavier Mirabel4,16, Emmanuelle Tresch5, Amaury Paumier6, Véronique Vendrely3,7,
Laetitia Dahan3,8, Olivier Glehen3,9, Frederique Vasseur4, Thomas Lacornerie10, Guillaume Piessen1,2,3,11,
Farid El Hajbi16, William B. Robb12,13, Stéphanie Clisant14, Andrew Kramar5,11, Christophe Mariette1,2,3,11
and Antoine Adenis3,11,15,16*
Abstract
Background: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer
consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most
commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue.
Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely
used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The
objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to
evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe
postoperative morbidity rate associated with these two neoadjuvant chemotherapeutic regimens (carboplatin-paclitaxel or
fluorouracil-oxaliplatin-folinic acid) when each is combined with the radiation regime utilized in the CROSS trial.
Methods/design: PROTECT is a prospective, randomized, multicenter, open arms, phase II trial. Eligible patients will have
a histologically confirmed adenocarcinoma or squamous cell carcinoma and be treated with neoadjuvant
radiochemotherapy followed by surgery for stage IIB or stage III resectable esophageal cancer. A total of 106 patients will
be randomized to receive either 3 cycles of FOLFOX combined to concurrent radiotherapy (41.4 Grays) or carboplatin and
paclitaxel with the same radiation regimen, using a 1:1 allocation ratio.
Discussion: This ongoing trial offers the unique opportunity to compare two standards of chemotherapy delivered with
a common regimen of preoperative radiation, in the setting of operable locally advanced esophageal or
gastro-esophageal junctional tumors.
Trial registration: NCT02359968 (ClinicalTrials.gov) (registration date: 9 FEB 2015), EudraCT: 2014-000649-62 (registration
date: 10 FEB 2014)
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Background
According to the 2012 GLOBOCAN survey, esophageal
cancer (EC) remains the 8th most common cancer
worldwide, with an estimated 456,000 new cases/year,
and the 6th most common cause of death from cancer
with approximately 400,000 deaths/year [1]. Even after
curative surgical treatment, the prognosis of EC is poor,
with a 5-year survival rate of nearly 40 % in patients
resected in a curative intent [2]. Because most patients
will present with local and/or distant recurrences during
follow-up, multimodal preoperative approaches, using
neoadjuvant chemoradiation (nCRT) or neoadjuvant
chemotherapy, have been introduced to improve out-
comes. In locally advanced EC, meta-analysis has shown
a significant survival benefit in favour of nCRT over sur-
gery alone, as well as a trend favouring nCRT over neo-
adjuvant chemotherapy [3]. However, in clinical practice,
results of this meta-analysis do not make the selection of
one nCRT regimen over another any easier. Moreover,
the radiation regimens used in the randomized trials
pooled in the meta-analysis are heterogeneous, with
inconsistencies in the total radiation dose used, the
number of fractions delivered, the length of treat-
ment, radiation field planning, dosimetry planning
and quality control. Although most regimens were
fluorouracil (FU) and cisplatin-based, heterogeneity in
the chemotherapy combinations used as well as the
number of cycles delivered also makes meaningful in-
terpretation difficult. Consequently, many clinicians
continue to use a chemotherapy regime of a fluoro-
pyrimidin and a platinum analogue combined with
concomitant radiotherapy.
The strongest evidence for the benefit of nCRT over
surgery alone comes from the recently updated CROSS
trial which compared nCRT with weekly carboplatin and
paclitaxel for 5 weeks and concurrent radiotherapy
(41.4Gy) to surgery only [4]. In this trial which included
366 patients with esophageal and gastro-esophageal
junctional tumors the complete resection rate was in-
creased from 69 % with surgery alone to 92 % with
the combined therapy with no increase in the postop-
erative mortality rate [5]. Ultimately, the nCRT in this
trial’s population provided a highly significant 34 %
reduction of the risk of death, as well as a significant
42 % reduction of the risk of relapse [4]. Currently, a
FU- and cisplatin-based nCRT regimen and the CROSS
combination may both continue to be considered as a
standard of treatment for locally advanced resectable
esophageal and gastro-esophageal junctional cancers [6].
The aim of the PROTECT trial is to evaluate the
complete resection rate and the severe postoperative mor-
bidity rate of two different preoperative regimens. It will
compare the use of a platinum analogue (oxaliplatin)- and
FU-based regimen (FOLFOX), with a platinum analogue
(carboplatin)- and paclitaxel-based regimen. Both chemo-
therapy regimens will be combined with concurrent
radiation as per the CROSS protocol in patients with




This randomized multicenter phase II trial will include
patients with infra-carinal squamous cell carcinoma
(SCC) or adenocarcinoma (ADC) of the esophagus and
Siewert type I or II tumors of the gastro-esophageal
junction who eligible for curative surgery. It compares
two different preoperative chemotherapy regimens
(FOLFOX or carboplatin-paclitaxel) both of which are
combined with concomitant neoadjuvant radiotherapy in
accordance with the CROSS regime.
Inclusion criteria
Patients will be considered for inclusion if they conform
to the following criteria:
✓ Resectable infra-carinal EC (beyond 25 cm from
the incisors) or Siewert type I or II gastro-
esophageal junctional cancers
✓ Invasive adeno or squamous cell carcinomas
✓ Stage IIB (T1 N1 M0 or T2 N1 M0) or stage III
(T3 N1 M0 or T4 N0 N1 M0) tumors according to
the 7th Union for International Cancer Control
(UICC) classification [7]
✓ Eastern Cooperative Oncology Group (ECOG)
performance status (PS) 0, 1 or 2
✓ Patients must be eligible for preoperative
chemoradiation with either FOLFOX or Paclitaxel-
carboplatin
✓ Age ≥ 18 and ≤ 75 years
✓ Peripheral neuropathy ≤ grade 1 according to the
NCI-CTC classification
✓ Adequate bone marrow, renal and liver function
[neutrophil count ≥ 1500/mm3, platelet count
≥ 100 000/mm3, haemoglobin ≥ 10 g/dl (after
transfusion, if required), creatinine < 15 mg/L,
clearance of creatinine (Cockcroft formulae)
≥ 60 ml/min, prothrombin time ≥ 60 %, AST and
ALT ≤ 2.5 × upper limit of normal, total bilirubin
< 1.5 × upper limit of normal, normal serum
albumin level)
✓ Start of treatment within 28 days after inclusion
✓ Negative pregnancy test (serum β-HCG) performed
less than 1 week prior to the beginning treatment in
females of reproductive age
✓ Patients must covered by government health
insurance
✓ Patients must provide written informed consent
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Exclusion criteria
Any of the following will exclude patients from partici-
pation in the trial:
– Stage I, IIA or stage IV EC or Siewert 3 gastro-
esophageal junctional tumors
– Contraindications for surgery related to patient
comorbidities: PaO2 < 60 mmHg, PaCO2 > 45 mmHg,
forced expiratory volume in one second < 1000 ml/s,
cirrhosis, myocardial infarction or on-going
coronary artery disease, severe peripheral arterial
occlusive disease (≥ stage II of the Leriche-Fontaine
classification), weight loss exceeding 15 % over a
6 months period, other serious illness or medical
conditions (such as left ventricular failure or
uncontrolled infection)
– Other malignant tumor within the last 5 years or
synchronous malignant tumor
– Pre-menopausal patients not using adequate
contraception
– Pregnant or breast-feeding woman
– Auditory disorders
– Other histological subtypes of EC or type I and II
gastro-esophageal junctional tumors which are not
either a SCC or ADC
– Tumors located at the pharyngo-esophageal junction,
the cervical esophagus, supra-carinal esophageal
tumors or type III gastro-esophageal junctional
tumors
– Distant metastases, including metastasis to supra-
clavicular nodes
– Recurrent laryngeal nerve palsy due to tumor invasion
– Tumor involvement of adjacent mediastinal structures
– Length and width of the tumor exceeding 8 and
5 cm, respectively
– Prior cervical, thoracic and/or abdominal
radiotherapy with field overlapping the proposed
radiotherapy field
– Tracheo-esophageal fistula or invasion of the tracheo-
bronchial airway
– Any other synchronous experimental drug treatment
– Previous hyper sensibility reaction to compounds
containing a fluoropyrimidin, platinum salt or a
taxane
– Peripheral sensory neuropathy with functional
impairment
– Yellow fever vaccination, prophylactic use of
phenytoin, live-attenuated vaccines
Endpoints
The primary endpoint is composite: it combines both
the complete resection (R0) rate and the severe post-
operative morbidity rate (grade ≥ 3) according to the
Clavien-Dindo classification [8].
Secondary endpoints are i) tumor regression grade ac-
cording to the Mandard classification [9] and complete
pathological response (ypT0N0) rate, ii) survival out-
comes with overall and disease-free survival measured
from the date of randomization, iii) safety criteria of
nCRT (number of adverse events, type of toxicities, and
severity of adverse events graded using National Cancer
Institute Common Terminology Criteria (NCI-CTC),
version 4.0), (iv) 30-day postoperative mortality and
morbidity according to the Clavien-Dindo classification,
with focused interest on post-operative cardio-respiratory
morbidities rates, v) quality of life assessed at baseline, the
day before surgery, and every 6 months after surgery, until
progressive disease or death, using the QLQC30 European
Organisation for Research and Treatment of Cancer
(EORTC) questionnaire, as well as the dedicated
esophageal module OES18, vi) correlation between
lung Dose-Volume-Histogram (DVH) and postopera-
tive respiratory morbidity, and viii) tolerance of the
preoperative regimen, estimated by the percentage of
patients who will receive the whole therapeutic sequence
without modification. Postoperative medical and surgical
complications will be detailed using a standardized defin-
ition [10] and classified according to the Dindo-Clavien
classification [8].
Randomization
Patients will be allocated randomly either to arm A:
FOLFOX + 41.4 Gy or arm B: Carboplatin-paclitaxel +
41.4 Gy (Fig. 1), in a 1:1 ratio. Randomization (CS-online
tool, Clinsight) will be centrally performed with the
minimization technique for the following stratification
factors: ECOG PS (0 vs. 1–2), stage (IIB vs. III), histology
(SCC vs. ADK), and centers.
Pre therapeutic work-up
Baseline assessment (within 28 days prior to the start of
treatment), will include: physical examination, measure-
ment of weight, height, ECOG PS, standard laboratory
tests (complete blood count, platelets, prothrombin rate,
creatinine, AST-ALT, total bilirubin, albumin, serum
β-HCG if applicable), ear, nose and throat examin-
ation, panendoscopy under general anaesthesia and a
bronchoscopy with biopsies for patients with a SCC,
esophagogastro-duodenoscopy with biopsies, laparo-
scopic exploration of the abdominal cavity to confirm
the absence of contraindications for surgery (hepatic
cirrhosis, hepatic or peritoneal metastases, or non-
resectable tumor), a feeding jejunostomy may also be
inserted during the laparoscopic procedure for pre-
operatively malnourished patients (more than 10 % of
weight loss prior to trial inclusion), ultrasound ex-
ploration of the cervical area, a computed tomog-
raphy (CT) scan of the neck, thorax, abdomen and
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pelvis, esophageal ultrasound endoscopy (EUS) exam-
ination, positon emission tomography (PET-CT) at
the investigator’s discretion.
Clinical tumor staging (cTNM) will be based on data
obtained from CT scan, EUS and PET-CT, and estab-
lished using the 7th UICC classification [7]. Quality of
life questionnaires QLQC30 and OES18 module will be
performed at baseline.
Before each cycle of chemotherapy, a physical examin-
ation, with documentation of adverse events will be per-
formed, as well as standard laboratory tests. After the
completion of nCRT tumor re-staging will be mandatory
and will include at least an esophagoscopy with a mini-
mum of four biopsies at the initial site of the tumor and
a CT-scan of the neck, thorax, abdomen and pelvis.
Treatment methods
Patients in arm A will receive 3 cycles of FOLFOX over
14 days. FU 400 mg/m2 will be given on Day 1 adminis-
tered as a 10-min intravenous bolus dose followed by
continuous intravenous infusion of 1600 mg/m2 over
2 days. Oxaliplatin 85 mg/m2, will be given as a 2-h
intravenous infusion plus Folinic acid 200 mg/m2 (or
calcium levofolinate 100 mg/m2) administered as a 2-h
intravenous infusion.
Arm B will receive 5 cycles of carboplatin-paclitaxel.
On days 1, 8, 15, 22 and 29, patients will receive Paclitaxel
50 mg/m2 and Carboplatin AUC 2 by intravenous
infusion.
With regards to concomitant radiotherapy, patient
position, definition of target volume and critical struc-
tures, simulation procedures and radiation technique
will be similar in both arms and will match the descrip-
tion provided in the supplementary appendix of the
CROSS trial [5]. A total dose of 41.4Gy will be given in
23 fractions of 1.8Gy, 5 fractions per week, starting the
first day of the first cycle of chemotherapy. All patients
will receive radiotherapy by external beam radiation
using a 3-D-conformal radiation technique. Though the
radiotherapy is done without intensity-modulated radio-
therapy, treatment report will follow the International
Commission on Radiation Units and Measurements 83
recommendations.
En bloc esophageal resection will be performed 4 to
8 weeks after the completion of nCRT through a trans-
thoracic approach with a two field extended lymphade-
nectomy (Ivor Lewis procedure) and in accordance
surgical quality criteria guidelines [11].
Data collection and follow-up
The data management team of the Methodology and
Biostatistics Unit of the Oscar Lambret Cancer Centre
will undertake data Management. A trial-specific data-
base will be created, tested and validated before the start
of data capture. This database will be developed using
Clinsight (ENNOV). The essential data necessary for
monitoring the primary and secondary endpoints will be
identified and managed at regular intervals throughout
the trial in collaboration with the coordinator and the
Oscar Lambret Cancer Centre Sponsorship Unit. The
electronic case report forms will be completed at each
investigator site. Treatment will continue unless one or
more of the following occur i) disease progression dur-
ing preoperative treatment (according to Response
Evaluation Criteria in Solid Tumors, version 1.1 [12]),
ii) death, iii) unacceptable toxicity, or, iv) withdrawal
of consent for any other reason.
Outpatient examination will be performed 1 month
after surgery (physical examination) and every 6 months
thereafter (Quality of life: EORTC QLQC30 and OES18
modules) for 5 years. At each 6 month follow up all
patients will have a clinical examination and thoraco-
abdominal CT scan. Other investigations will be per-
formed as required.
Participating centers
Five centers (Lille, Bordeaux, Lyon, Nantes/Angers,
Marseille; France) will participate in this study.
Fig. 1 Study flow chart. R: randomization, cy: cycles, RT: radiotherapy, CarboP-pacliT: carboplatin-paclitaxel, FOLFOX: fluorouracil, leucovorin,
oxaliplatin, *23 fractions of 1.8Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
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Statistical analyses and sample size
This trial is based on a Bryant and Day two-stage design
with stopping rules for unacceptable results for rates of
R0 resections or excessive toxicity in terms of severe
post-operative morbidity in each arm. According to the
literature, the expected complete R0 resection rate
should be at minimum 75 % and severe postoperative
toxicity rate should be most 45 %. Fifty-three patients in
each arm (48 evaluable) need to be included for a total
of 106 patients according to following parameters:
 pR0 = 0.75 and pT0 = 0.55 corresponding respectively
to an unacceptable R0 rate of ≤75 % and an
unacceptable severe postoperative toxicity rate of
45 % or more.
 pR1 = 0.90 and pT1 = 0.75 corresponding to an
acceptable R0 rate of 90 % or more, and an
acceptable severe postoperative morbidity rate of
25 % or more, respectively.
 Errors rates αR = 0.10, αT = 0.10, and β = 0.15
corresponding respectively to a false positive error
rate for response of 10 %, a false positive error rate
for toxicity of 10 %, and 85 % power.
 Results will be evaluated after a first stage and the
decision on continuing with one or both arms will
be based on the following rules. In the first 20
patients in each arm, if there are ≤ 15 R0 resections
or ≥ 9 patients with severe postoperative morbidity
(≤11 patients without toxicity) then that treatment
arm will not be considered to be of sufficient merit
to consider further evaluation. If both treatment
arms fail to satisfy the decision rules, then the trial
will be stopped after this initial stage. If both
treatment arms satisfy the decision rules, then the
trial will continue to the second stage. If only one
treatment arm satisfies the decision rules, then
continuation of the trial with 1 or 2 arms will
depend on the recommendations of the Data
Monitoring Committee.
 During a second stage, each treatment will be
evaluated after a total of 48 patients in each arm
can be evaluated. Either arm will be considered of
insufficient value if there are ≤ 39 R0 resections
or ≥ 18 patients with severe post operative toxicity
(≤30 patients without severe toxicity). Results at
the end of the trial will allow a go/no go decision
to be made for continuing to a phase III trial.
Ethics and safety
The study protocol has been approved by our local eth-
ics committee (CPP Nord-Ouest IV, November 4th,
2014), and by our national regulatory agency (Agence
Nationale de Sécurité du Médicament et des Produits de
Santé, August 29th, 2014).
Discussion
The present trial offers the unique opportunity to
compare 2 standards of chemotherapy delivered with a
common regimen of preoperative radiation, in the set-
ting of operable locally advanced esophageal or gastro-
esophageal junctional tumors.
Paradoxically, before the CROSS trial publication in
2012 [5], evidence for a benefit of nCRT over surgery re-
lied solely on randomized studies that mainly failed to
demonstrate a survival benefit. Most of these trials were
underpowered and the significant survival advantage of
nCRT over surgery alone only appeared with meta-
analysis [3]. As most of the nCRT regimens included in
such meta-analysis were FU- and cisplatin-based, this
regimen became a standard of care in many countries.
Recent data, in the setting of definitive chemoradiation,
suggested that the use oxaliplatin could be more con-
venient and safer, with less sudden death, compared to
cisplatin [13]. Many oncologists have therefore changed
their practice from using a nCRT regimen with FU and
cisplatin, to a nCRT regimen with FOLFOX.
The carboplatin/paclitaxel combination is a key com-
ponent of a nCRT regimen which has demonstrated a
significant survival benefit over surgery alone, in the
unique, well designed and adequately powered CROSS
trial [4, 5]. However, this regimen has not been univer-
sally accepted into everyday practice, potentially because
of selection bias which could have resulted in less
nCRT-induced complications [6]. Indeed, most tumors
in the CROSS trial arose from the lower third of the
esophagus and gastro-esophageal junction and this usu-
ally correlates with less postoperative morbidity com-
pared to upper third tumors. Moreover, the lung volume
spared from radiation is greater in gastro-esophageal
junctional tumors than in upper third cancers (a critical
point in the development of radiation-induced pneu-
monitis and subsequent postoperative mortality). The fa-
vorable impact of the CROSS nCRT regimen may also
be explained by a moderate total dose of radiation
(41.4 Gy), smaller radial margins than in other trials,
and modern dosimetry with 3D planning [5], which all
improved the safety of treatment and of subsequent sur-
gery. Further, the favorable impact of this regimen could
possibly result from the fact that it did not include cis-
platin, a compound that has been found to be associated
with more sudden deaths [13], and more thrombo-
embolic events [14] than oxaliplatin-based regimens.
Finally, as an exploratory study, we will analyse
whether any relationship exists between the characteris-
tics of the delivered radiotherapy, such as the dose deliv-
ered to lung tissue, and severe postoperative pulmonary
toxicities. This question has been addressed in at least 2
retrospective studies [15, 16], without a consensus being
reached on what characteristics of radiotherapy predict
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postoperative pulmonary toxicity. In the current ancil-
lary study we will evaluate this putative relationship and
in addition evaluate the role of both tumor location and
the allocated preoperative chemotherapy regimen, as
both of these parameters have been suspected to interact
with postoperative pulmonary toxicity [17, 18]. The full
DVH instead of thresholds will be analyzed to be able to
find any correlation between dose, volume and toxicity.
Conclusion
To summarize, in patients with resectable locally ad-
vanced esophageal and gastro-esophageal junctional can-
cers who are eligible for curative treatment, it is of great
clinical interest to compare the two current standards of
neoadjuvant chemotherapy (carboplatin/paclitaxel-based
and oxaliplatin/FU-based) combined with a common
standardized protocol for concomitant radiotherapy. Be-
fore performing a formal phase 3 trial, we first designed
this randomized phase 2 trial to investigate the complete
resection rate and the severe postoperative morbidity
rate of these two regimens.
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